Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.48 |
| ▸ | NMT2 | O60551 | 5/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | CD40 | P25942 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576026 | 0.99 | NMT1 (0.46) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL20272636 | 0.99 | NMT1 (0.46) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL18359086 | 0.98 | GNAI3 (0.47) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL14707968 | 0.94 | NMT1 (0.47) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL14642615 | 0.94 | GNAI3 (0.44) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL14642614 | 0.94 | GNAI3 (0.49) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL21233587 | 0.93 | NMT1 (0.43) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL15084741 | 0.93 | NMT1 (0.42) | NMT1NMT2GNAI3GNAO1GNAI1 | |
| SCHEMBL20706553 | 0.91 | GNAI3 (0.57) | GNAI3GNAO1GNAI1CD40TLR2 | |
| SCHEMBL20272608 | 0.91 | GNAI3 (0.57) | GNAI3GNAO1GNAI1CD40TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | NMT1 1232/4885NMT2 1694/4885GNAI3 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.